<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649101</url>
  </required_header>
  <id_info>
    <org_study_id>ZCHBC-007</org_study_id>
    <nct_id>NCT02649101</nct_id>
  </id_info>
  <brief_title>Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer</brief_title>
  <official_title>Thalidomide Plus Chemotherapy Versus Chemotherapy Alone: A Phase II Study in Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sixty advanced breast cancer patients are planed to enrolled in this clinical trial. Forty&#xD;
      patients are enrolled into thalidomide plus chemotherapy group. Twenty patients are enrolled&#xD;
      into chemotherapy alone group. There is no restriction on chemotherapy regimen and lines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study compares the combination of thalidomide and chemotherapy with chemotherapy alone&#xD;
      for the treatment of stage IV breast cancer. Efficacy and safety of the&#xD;
      chemotherapy-thalidomide combination will be evaluated. Assessing the isolated effects of&#xD;
      thalidomide in a setting where pre and post treatment serum specimens can be obtained will&#xD;
      provide essential information about the mechanisms by which vascular endothelial growth&#xD;
      factor(VEGF) inhibition affects tumor growth, and represents an ideal opportunity to evaluate&#xD;
      the molecular effects of thalidomide on breast tumor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>Change from Baseline RECIST at 6 months was assessed every 6 weeks up to 24 weeks. Data collection is from date of randomization until the date of first documented progression assessed up to 6 months.</time_frame>
    <description>PFS is defined as the months that from the anticipation of the clinical-trial to the progress of breast cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>Survival assessed every 8 weeks up to 100 months following objective disease progression. Data collection is from date of randomization until the date of death from any cause, assessed up to 100 months.</time_frame>
    <description>OS is defined as the months that from the anticipation of the clinical-trial to the death of patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>thalidomide plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>thalidomide tablet 100mg qn po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Physician's choice chemotherapy. No constraints of the choice of chemotherapy drugs and regimens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Thalidomide tablet 100mg qn po.</description>
    <arm_group_label>thalidomide plus chemotherapy</arm_group_label>
    <other_name>Contergan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician's choice chemotherapy</intervention_name>
    <description>Investigators will declare no constraint of regimens.</description>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_label>thalidomide plus chemotherapy</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. inclusion criteria:&#xD;
&#xD;
               -  Women &gt;/= 18 and &lt; 65 years of age .&#xD;
&#xD;
               -  Histologically or cytologically confirmed breast cancer with evidence of&#xD;
                  metastatic disease. (Note: the participant must be recovered from any clinically&#xD;
                  significant toxicity thereof last therapy.)&#xD;
&#xD;
               -  ECOG performance status 0-2.&#xD;
&#xD;
               -  Adequate bone marrow, kidney and liver function.&#xD;
&#xD;
               -  ER/PR breast cancer positive patients must have received and progressed on at&#xD;
                  least one endocrine therapy (adjuvant or metastatic), or have disease that the&#xD;
                  treating physician believes to be inappropriate for endocrine therapy.&#xD;
&#xD;
          2. exclusion criteria:&#xD;
&#xD;
               -  Prior treatment with thalidomide.&#xD;
&#xD;
               -  Patients with HER2 positive disease.&#xD;
&#xD;
               -  Untreated and/or uncontrolled brain metastases.&#xD;
&#xD;
               -  Prior malignancy unless curatively treated and disease-free for &gt; 5 years prior&#xD;
                  to study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer&#xD;
                  of the cervix, DCIS or stage I grade 1 endometrial cancer allowed.&#xD;
&#xD;
               -  Known HIV (Human Immunodeficiency Virus) infection.&#xD;
&#xD;
               -  Pregnant or breast-feeding women.&#xD;
&#xD;
               -  Bilateral invasive breast cancer.&#xD;
&#xD;
               -  Cardiac and thrombotic disease or risk for same as judged by Investigator.&#xD;
&#xD;
               -  Other serious illness or medical conditions such as (partial list- review with&#xD;
                  Investigator) history of significant neurologic or psychiatric disorders that&#xD;
                  would prohibit the understanding and giving of informed consent, active&#xD;
                  uncontrolled infection, active peptic ulcer, unstable diabetes mellitus or&#xD;
                  subjects with symptomatic, intrinsic lung disease resulting in dyspnea at rest.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiaojia wang, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>lei lei, master</last_name>
    <phone>+8613750802564</phone>
    <email>leilei1241@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xiaojia wang, doctor</last_name>
    <phone>+8613906500190</phone>
    <email>wangxj@zjcc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojia Wang, PHD</last_name>
      <phone>86 13906500190</phone>
      <email>wxiaojia0803@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jian Huang, Doctor</last_name>
      <phone>86 13588048995</phone>
      <email>huang_jian22@aliyun.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaojia Wang, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>December 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>LeiLei</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

